| Abstract: |
Adjuvant therapy for pancreas adenocarcinoma in 2012 includes consideration of systemic therapy based on high level evidence and combined chemoradiotherapy based on less robust data. Current major adjuvant questions are examining the role of the addition of a second agent, either cytotoxic or targeted agent, to gemcitabine and whether or not the utilization of combined chemoradiotherapy improves overall survival. Progress to date has been modest and incremental in the adjuvant setting. J. Surg. Oncol. 2013;107:78-85. © 2012 Wiley Periodicals, Inc. Copyright © 2012 Wiley Periodicals, Inc. |
